Zhongguancun (000931.SZ) subsidiary's BDB tablet drug clinical trial approved

Zhitong Finance APP News, Zhongguancun (000931.SZ) announced that its subsidiary Shandong Huasu Pharmaceutical Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" for BDB tablets approved and issued by the National Medical Products Administration. The drug is used to treat essential hypertension and is a new fixed-dose combination containing known active ingredients, and has not been marketed domestically or abroad. Its individual components have demonstrated efficacy and safety in clinical practice, and their combined use is recommended by clinical guidelines.